The Banff Classification of Renal Allograft Pathology is used internationally for scoring and classifying rejection in kidney transplant biopsies. This score system has gone through a number of modifications since it was first published in 1993. Criteria for diagnosis are changing as new knowledge is accumulated, studies demonstrate the importance of features not previously considered, and ancillary studies are developed for more precise determination of graft dysfunction causes. The 2005-updated Banff schema, published in 2007 (1), recognizes antibodymediated rejection (AMR), in addition to the traditional category of acute and chronic active T-cell-mediated rejection. The more sophisticated approach to renal biopsy study permits refinement in diagnosis and specific therapeutic approaches.

The Banff Classification of Renal Allograft Pathology is a useful tool for diagnosing kidney transplant rejection, but its application in low-income countries faces challenges due to limited resources and limited expertise.

Renal Allograft Rejection: Difficulties in Biopsy Diagnosis in Low‐Income Countries

Key Takeaway: The Banff Classification of Renal Allograft Pathology is a useful tool for diagnosing kidney transplant rejection, but its application in low-income countries faces challenges due to limited resources and limited expertise.